Needed to develop pricing and market access estimates for a biologic with expected follow-on indications.
CLIENT TYPE: PAYER STRATEGY LEAD
NEEDS: After completion of Phase II studies for an internal program a payer strategy lead needed to develop robust pricing and market access assumptions for a biologic product to inform strategic forecasting efforts.
WHY CLEARVIEW: ClearView has deep subject matter expertise within the pricing and market access space and has experience utilizing these projects as a bridge into broader commercial strategy development in preparation for the launch of innovative products.
NEED: Develop pricing and market access for a biologic compound with a complex lifecycle plan as it approaches Phase III clinical trials
RESULTS: ClearView developed a multi-pronged approach to develop robust and defensible pricing and access assumptions within an aggressive project timeline. ClearView used a combination of pricing analogues, primary research with a mix of P&T-level Payer decision makers, and comparator cost-effectiveness analyses to develop baseline, upside, and downside pricing and market access estimates for the client’s strategic forecast.
IMPACT: Our work clarified price/volume tradeoff assumptions and identified a clear “tipping-point” at which pricing could result in more aggressive access restriction. In addition, we provided strategic recommendations on how pricing for the lead indication could impact future indications and where rebate contracts, in the U.S., could mitigate future risks.